Pfizer and BioNTech will seek regulatory clearance of their coronavirus vaccine

Pfizer and its German partner BioNTech on Friday will submit their coronavirus vaccine, which was 95 percent effective in a clinical trial, to be considered for emergency authorization.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.